Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Notes Payables (2021 - 2022)

Verrica Pharmaceuticals (VRCA) has 2 years of Notes Payables data on record, last reported at $42.3 million in Q2 2022.

  • For Q2 2022, Notes Payables rose 3.14% year-over-year to $42.3 million; the TTM value through Jun 2022 reached $42.3 million, up 3.14%, while the annual FY2021 figure was $41.7 million, N/A changed from the prior year.
  • Notes Payables reached $42.3 million in Q2 2022 per VRCA's latest filing, up from $42.0 million in the prior quarter.
  • Across five years, Notes Payables topped out at $42.3 million in Q2 2022 and bottomed at $40.0 million in Q1 2021.